Search
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalEvolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface, resulting in more LDL receptors on the surface of the liver to remove LDL-C from the blood. … PCSK9 is a protein that targets LDL receptors for degradation, therefore reducing the liver's ability to remove LDL-cholesterol (LDL-C), or "bad" cholesterol, from the blood.
Von Willebrand factor human
go.drugbank.com/drugs/DB13133ApprovedInvestigational[L1878] A recombinant form of vWF, [vonicog alfa], is also available to enhance production and avoid the theoretical risk of pathogen transmission from plasma donors.[A32262] … The human vWF is used to manage and control bleeding episodes in patients with von Willebrand disease and hemophilia A. It was first approved by the FDA in 2015.
Mixtures: ENJEKSİYON/İNFÜZYON İÇİN TOZ VE ÇÖZÜCÜ, ENJEKSİYON/İNFÜZYON İÇİN TOZ VE ÇÖZÜCÜOliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin … [A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeOdevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigationalOdevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC
Oxymetholone
go.drugbank.com/drugs/DB06412ApprovedIllicitIn 2009, no producers of oxymetholone were identified worldwide (SRI 2009), but it was available from 14 suppliers, including 8 U.S. suppliers (ChemSources 2009). … Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth
Human vaccinia virus immune globulin
go.drugbank.com/drugs/DB14112ApprovedInvestigationalThe IgG fraction is purified by the anion-exchange column chromatography method and the solution is solvent/detergent-treated to sterilize the compound [A33814]. … Human vaccinia immune globulin (VIG) is a sterile solution containing the purified gamma globulin (IgG) fraction of plasma taken from healthy donors previously vaccinated with live vaccinia virus vaccine
Chymotrypsin
go.drugbank.com/drugs/DB09375ApprovedInvestigationalVet approvedWithdrawnChymotrypsin is the most abundant pancreatic proteases that represent up to 10-20% of the total protein synthesized by the exocrine pancreas [A32637]. … Like most proteolytic enzymes, chymotrypsin is activated from its inactive zymogen precursor, chymotrypsinogen, in presence of [DB11237].
Dextropropoxyphene
go.drugbank.com/drugs/DB00647ApprovedIllicitWithdrawnDue to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. … The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect.
Mixtures: Darvocet-N 50, Darvocet-N 100Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTestosterone
go.drugbank.com/drugs/DB00624ApprovedInvestigational[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.[A186943] … Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.
International brands: Bio-T-GelTecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigational[L3626, L3614] Tecovirimat was later approved by Health Canada in December 2021,[L39397] followed by the approval from the European Commission in January 2022. … [A35131,A35143] Tecovirimat was approved by the FDA in July 2018 as the first drug ever approved to treat smallpox.